CTKB
NASDAQCytek Biosciences Inc.
Price$3.96-0.03 (-0.75%)
01:30 PM07:45 PM
News · 26 weeks49+186%
2025-12-142026-06-07
Mix2990d
- Insider14(48%)
- Other6(21%)
- SEC Filings5(17%)
- Earnings2(7%)
- Leadership2(7%)
Latest news
25 items- INSIDERDirector Ball Jack converted options into 43,973 shares, increasing direct ownership by 103% to 86,678 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERSEC Form 4 filed by Director Muir Glenn P4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERSEC Form 3 filed by new insider Muir Glenn P3 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERSEC Form 4 filed by Director Chin Richard4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERDirector Imper Vera converted options into 43,973 shares, increasing direct ownership by 280% to 59,679 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERDirector Neff Deborah J converted options into 43,973 shares, increasing direct ownership by 280% to 59,679 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERDirector Holder Michael converted options into 43,973 shares, increasing direct ownership by 263% to 60,694 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- PRCytek Biosciences to participate at the Singular Research's Las Vegas Invitational ConferenceFREMONT, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that the company will be participating in the upcoming Singular Research's Las Vegas Invitational Conference taking place June 14-16, 2026. Cytek management is scheduled to participate in a presentation on Monday, June 15th at 11:00 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generation o
- PRMarvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600NEW YORK, June 5, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 22, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from S&P MidCap 400 and S&P SmallCap 600 are no longer representative of the mid-cap and small-cap market space, respectively. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name ActionCompany NameTickerGICS SectorJune 22, 2026
- PRCytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026FREMONT, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- At CYTO 2026, the industry's premier flow cytometry conference, spectral flow cytometry leader Cytek Biosciences, Inc. (NASDAQ:CTKB) will showcase its expanding portfolio of end-to-end cell analysis solutions, including the public debut of a new 7-laser Cytek Borealis full spectrum flow cytometer, as well as automation-ready configurations of the Cytek Aurora Evo system. The 39th annual Congress, themed Cytometry: The Next Wave, will spotlight emerging technologies shaping the future of the field. Cytek continues to play a central role in that evolution, advancing high-parameter analysis through innovations designed to increase flexibilit
- SECSEC Form 8-K filed by Cytek Biosciences Inc.8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
- SECSEC Form SD filed by Cytek Biosciences Inc.SD - Cytek Biosciences, Inc. (0001831915) (Filer)
- INSIDERDirector Holder Michael converted options into 1,454 shares, increasing direct ownership by 10% to 16,721 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERDirector Chin Richard converted options into 6,107 shares, increasing direct ownership by 38% to 22,392 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERCHIEF TECHNOLOGY OFFICER Yan Ming converted options into 22,179 shares and covered exercise/tax liability with 5,532 shares, increasing direct ownership by 0.34% to 4,932,580 units (SEC Form 4) (tax withholding)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERSVP, GLOBAL SALES AND SERVICES Busque Philippe converted options into 10,464 shares and covered exercise/tax liability with 2,685 shares, increasing direct ownership by 22% to 43,466 units (SEC Form 4) (for withholding tax)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERPRESIDENT AND CEO Jiang Wenbin converted options into 80,062 shares and covered exercise/tax liability with 25,542 shares, increasing direct ownership by 1% to 5,477,203 units (SEC Form 4) to cover taxes4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERChief Financial Officer Mccombe William D. converted options into 25,719 shares and covered exercise/tax liability with 9,229 shares, increasing direct ownership by 17% to 111,177 units (SEC Form 4) (for tax liability)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERCHIEF LEGAL OFFICER Barnett Valerie covered exercise/tax liability with 8,719 shares and converted options into 24,295 shares, increasing direct ownership by 12% to 150,012 units (SEC Form 4) to satisfy withholding obligation4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)
- PRA Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in MedtechVMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at
- SECSEC Form 10-Q filed by Cytek Biosciences Inc.10-Q - Cytek Biosciences, Inc. (0001831915) (Filer)
- SECCytek Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
- PRCytek Biosciences Reports First Quarter 2026 Financial ResultsFREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Total revenue for the first quarter of 2026 was $44.1 million, representing a 6% increase compared to the first quarter of 2025Service revenue for the first quarter of 2026 was $15.4 million, representing a 15% increase compared to the first quarter of 2025Total recurring revenue, comprised of service and reagent revenues, reached $18.4 million in the first quarter. On a trailing-12-month basis, recurring revenue represented 35% of
- SECSEC Form DEFA14A filed by Cytek Biosciences Inc.DEFA14A - Cytek Biosciences, Inc. (0001831915) (Filer)
CTKB FAQ
6 questionsWhere does CTKB stock trade?
Cytek Biosciences Inc. (CTKB) is listed on NASDAQ.What sector and industry is CTKB in?
Cytek Biosciences Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Cytek Biosciences Inc. go public?
Cytek Biosciences Inc. (CTKB) completed its IPO in 2021.What are analysts saying about CTKB?
Cytek Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $600.00 price target on 2025-12-02. Recent price targets range from $400.00 to $2000.00.What companies are similar to CTKB?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare CTKB side-by-side with any of them on Quantisnow.How can I track CTKB on Quantisnow?
Quantisnow aggregates Cytek Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CTKB to receive live email and push alerts on every new disclosure.